Monday, November 13, 2023
Biovica, a prominent player in cancer monitoring, has recently entered into a commercial partnership agreement for the Nordics with Axlab A/S to promote and distribute the DiviTum® TKa assay.
Axlab, recognized as a top-tier brand in cancer screening and diagnostics in the Nordics with a strong history of successful sales, will facilitate a systematic sales approach to Nordic countries. This collaboration aims to make the DiviTum TKa assay easily accessible for oncology departments and cancer centers throughout the Nordics. The introduction of the DiviTum TKa assay to the Nordics is seamlessly aligned with our organizational goals, fortifying our market position and advancing our mission of providing patient-centric treatment monitoring.
In the Nordics, approximately 5,700 women receive a diagnosis of metastatic breast cancer each year. This represents around 6 percent of the total market potential for patients with metastatic breast cancer in the combined area of Europe Big-5 and the Nordics. The partnership with Axlab is expected to play a crucial role in the Nordic market introduction. The initial focus will be on engaging breast oncologists and decision-makers, fostering awareness and demand, and integrating the test into guidelines.
Source: biovica.com
